Mibefradil: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{CMG}},{{SS}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407797796
| IUPAC_name = (1''S'',2''S'')-2-(2-((3-(1''H''-benzo[''d'']imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
| image = Mibefradil.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CONS|mibefradil}}
| MedlinePlus = a607007
| pregnancy_category = 
| legal_status = Withdrawn from market
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 116644-53-2
| ATC_prefix = C08
| ATC_suffix = CX01
| PubChem = 60662
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01388
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 27B90X776A
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08217
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 45816
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 54673
<!--Chemical data-->
| C=29 | H=38 | F=1 | N=3 | O=3
| molecular_weight = 495.63 g/mol
| smiles            = CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
| InChI            = 1/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
| InChIKey          = HBNPJJILLOYFJU-VMPREFPWBB
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey      = HBNPJJILLOYFJU-VMPREFPWSA-N
}}
'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].  
'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].  
It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref>
It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref>
On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref>
On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref>
==References=={{Reflist}}
 
==References==
 
{{Reflist}}
{{Membrane transport modulators}}
{{Membrane transport modulators}}


Revision as of 15:27, 23 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Sheng Shi, M.D. [2]


Mibefradil
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa607007
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • Withdrawn from market
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC29H38FN3O3
Molar mass495.63 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers. It is nonselective.[1] On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]

References

  1. ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
  2. ↑ Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html

Template:Membrane transport modulators

Retrieved from "https://www.wikidoc.org/index.php?title=Mibefradil&oldid=999545"